-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
While Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders have made 94% in 3 years, increasing losses might now be front of mind as stock sheds 17% this week
While Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders have made 94% in 3 years, increasing losses might now be front of mind as stock sheds 17% this week
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shareholders might be concerned after seeing the share price drop 17% in the last week. But over three years, the returns would have left most investors smiling In fact, the company's share price bested the return of its market index in that time, posting a gain of 94%.
Since the long term performance has been good but there's been a recent pullback of 17%, let's check if the fundamentals match the share price.
See our latest analysis for Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last 3 years Arcturus Therapeutics Holdings saw its revenue shrink by 4.0% per year. Despite the lack of revenue growth, the stock has returned 25%, compound, over three years. If the company is cutting costs profitability could be on the horizon, but the revenue decline is a prima facie concern.
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
NasdaqGM:ARCT Earnings and Revenue Growth August 12th 2022We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So we recommend checking out this free report showing consensus forecasts
A Different Perspective
The last twelve months weren't great for Arcturus Therapeutics Holdings shares, which performed worse than the market, costing holders 66%. The market shed around 10%, no doubt weighing on the stock price. Investors are up over three years, booking 25% per year, much better than the more recent returns. Sometimes when a good quality long term winner has a weak period, it's turns out to be an opportunity, but you really need to be sure that the quality is there. It's always interesting to track share price performance over the longer term. But to understand Arcturus Therapeutics Holdings better, we need to consider many other factors. For instance, we've identified 1 warning sign for Arcturus Therapeutics Holdings that you should be aware of.
But note: Arcturus Therapeutics Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Arcturus治疗控股公司。纳斯达克(Sequoia Capital:ARCT)股东在看到上周股价下跌17%后可能会感到担忧。但在三年的时间里,这些回报会让大多数投资者微笑。事实上,该公司的股价超过了同期其市场指数的回报,涨幅为94%。
由于长期表现良好,但最近出现了17%的回调,让我们看看基本面是否与股价匹配。
查看我们对Arcturus Treateutics Holdings的最新分析
Arcturus治疗控股公司在过去的12个月里没有盈利,我们不太可能看到它的股价和每股收益(EPS)之间有很强的相关性。可以说,收入是我们的下一个最佳选择。当一家公司没有盈利时,我们通常预计会看到良好的收入增长。正如你可以想象的那样,快速的收入增长,如果保持下去,往往会带来快速的利润增长。
在过去的三年中,Arcturus治疗控股公司的收入以每年4.0%的速度下降。尽管收入增长乏力,但该股在三年内的复合回报率为25%。如果该公司正在削减成本,盈利可能即将到来,但收入的下降是一个表面上看担忧。
你可以在下面看到收入和收入是如何随着时间的推移而变化的(点击图片可以发现确切的价值)。
NasdaqGM:ARCT收益和收入增长2022年8月12日我们很高兴地报告,这位首席执行官的薪酬比类似资本公司的大多数首席执行官都要低。关注首席执行官的薪酬总是值得的,但更重要的问题是,该公司是否会在未来几年实现盈利增长。因此,我们建议您查看以下内容免费显示共识预测的报告
不同的视角
过去12个月对Arcturus治疗控股公司的股票来说并不是很好,该公司的表现逊于大盘,持有者损失了66%。股市下跌了约10%,无疑拖累了股价。投资者在三年多的时间里上涨了25%,比最近的回报好得多。有时候,当一个高质量的长期赢家有一个疲软的时期,它被证明是一个机会,但你真的需要确保质量在那里。跟踪股价的长期表现总是很有趣的。但为了更好地了解Arcturus Treateutics Holdings,我们需要考虑许多其他因素。例如,我们已经确定Arcturus Treateutics Holdings的1个警告标志这一点你应该知道。
但请注意:Arcturus Treateutics Holdings可能不是买入的最佳股票。所以让我们来看看这个免费过去有盈利增长(以及进一步增长预测)的有趣公司名单。
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧